In addition, the pleiotropic actions of SGLT2 inhibitors—including anti-inflammatory, antioxidative, endothelial-protective, and anti-arrhythmic effects—have been highlighted in recent reviews [46], providing a mechanistic explanation for their consistent cardiovascular benefits observed in major outcome trials such as EMPA-REG [8], DAPA-HF [47], and DELIVER [48]. This evidence concerns the gene SLC5A2 and hydrops fetalis.